Bioaffinity Technologies, Inc. (BIAF) - 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Bioaffinity Technologies, Inc. on January 26, 2024. The report details corporate governance actions taken by the Compensation Committee regarding executive compensation and the adoption of a new incentive plan.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. The document focuses exclusively on compensation arrangements and plan adoptions.
Material Changes and Compensation Actions
- Management Incentive Bonus Plan: On January 26, 2024, the Compensation Committee adopted the Management Incentive Bonus Plan to align employee efforts with strategic goals. Awards may be paid in cash or equity based on qualitative or quantitative performance standards.
- 2023 Executive Bonuses: Discretionary bonuses were approved for six executives for calendar year 2023. Payments are structured as 50% cash and 50% restricted stock, payable on or before January 31, 2024.
- Executive Bonus Amounts:
- Maria Zannes: $75,000
- Vivienne Rebel: $100,000
- Michael Dougherty: $100,000
- Timothy Zannes: $21,000
- Xavier Reveles: $52,500
- Steven Girgenti: $37,500
- Michael Dougherty Offer Letter Amendment: An amendment was approved to Mr. Dougherty's offer letter. It stipulates that any unvested portion of his prior restricted stock award will vest immediately upon a Change in Control.
Guidance, Outlook, and Risks
The filing contains no financial guidance, outlook, or discussion of general business risks. The primary contingency noted is the vesting acceleration of Mr. Dougherty's equity in the event of a Change in Control.
Key Facts for Investor Verification
- Verify the total cash outflow of $292,500 (50% of total bonuses) scheduled for payment by January 31, 2024.
- Confirm the number of restricted stock shares to be issued, which depends on the closing stock price on January 31, 2024.
- Review the full text of the Management Incentive Bonus Plan (Exhibit 10.1) for specific performance metrics.
- Monitor the company's capitalization for dilution resulting from the issuance of restricted stock to executives.